Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2338-2343
doi: 10.1161/hc4401.098432
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, D.
Right arrow Articles by Yan, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.
Right arrow Articles by Yan, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITROGLYCERIN
Related Collections
Right arrow Gene expression
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2001;104:2338.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance

Dongsoo Kim, MD; Sergei D. Rybalkin, PhD; Xinchun Pi, MS; Yining Wang, MD; Changxi Zhang, MD; Thomas Munzel, MD; Joseph A. Beavo, PhD; Bradford C. Berk, MD PhD; Chen Yan, PhD

From the Department of Medicine (D.K., X.P., C.Z., B.C.B., C.Y.) and Department of Surgery (Y.W.), University of Rochester, Rochester, NY; the Department of Pharmacology, University of Washington, Seattle (S.D.R., J.A.B.); and the Division of Cardiology, University of Eppendorf, Hamburg, Germany (T.M.).

Correspondence to Chen Yan, PhD, Center for Cardiovascular Research, University of Rochester, 601 Elmwood Ave, Box 679, Rochester, NY 14642-8679. E-mail chen_yan{at}urmc.rochester.edu

Background— The efficacy of nitroglycerin (NTG) as a vasodilator is limited by tolerance, which develops shortly after treatment begins. In vascular smooth muscle cells (VSMCs), NTG is denitrated to form nitric oxide (NO), which activates guanylyl cyclase and generates cGMP. cGMP plays a key role in nitrate-induced vasodilation by reducing intracellular Ca2+ concentration. Therefore, one possible mechanism for development of nitrate tolerance would be increased activity of the cGMP phosphodiesterase (PDE), which decreases cGMP levels.

Methods and Results— To test this hypothesis, rats were made tolerant by continuous infusion of NTG for 3 days (10 µg · kg-1 · min-1 SC) with an osmotic pump. Analysis of PDE activities showed an increased function of Ca2+/calmodulin (CaM)–stimulated PDE (PDE1A1), which preferentially hydrolyzes cGMP after NTG treatment. Western blot analysis for the Ca2+/CaM-stimulated PDE revealed that PDE1A1 was increased 2.3-fold in NTG-tolerant rat aortas. Increased PDE1A1 was due to mRNA upregulation as measured by relative quantitative reverse transcription–polymerase chain reaction. The PDE1-specific inhibitor vinpocetine partially restored the sensitivity of the tolerant vasculature to subsequent NTG exposure. In cultured rat aortic VSMCs, angiotensin II (Ang II) increased PDE1A1 activity, and vinpocetine blocked the effect of Ang II on decrease in cGMP accumulation.

Conclusions— Induction of PDE1A1 in nitrate-tolerant vessels may be one mechanism by which NO/cGMP-mediated vasodilation is desensitized and Ca2+-mediated vasoconstriction is supersensitized. Inhibiting PDE1A1 expression and/or activity could be a novel therapeutic approach to limit nitrate tolerance.


Key Words: nitrates • phosphodiesterase • vasculature




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
J. Am. Coll. Cardiol., January 13, 2009; 53(2): 207 - 215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. S. Baliga, L. Zhao, M. Madhani, B. Lopez-Torondel, C. Visintin, D. Selwood, M. R. Wilkins, R. J. MacAllister, and A. J. Hobbs
Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 861 - 869.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Sayed, D. D. Kim, X. Fioramonti, T. Iwahashi, W. N. Duran, and A. Beuve
Nitroglycerin-Induced S-nitrosylation and Desensitization of Soluble Guanylyl Cyclase Contribute to Nitrate Tolerance
Circ. Res., September 12, 2008; 103(6): 606 - 614.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J, June 1, 2008; 22(6): 1849 - 1860.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion
Phosphodiesterase regulation of nitric oxide signaling
Cardiovasc Res, July 15, 2007; 75(2): 303 - 314.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W. J. Perkins, M. Taniguchi, D. O. Warner, E. N. Chini, and K. A. Jones
Reduction in soluble guanylyl cyclase-specific activity following prolonged treatment of porcine pulmonary artery with nitric oxide
Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L84 - L95.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. R. Thomas, J. M. DiFabio, T. Gori, and J. D. Parker
Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans: Evidence of a Free-Radical-Mediated Mechanism
J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1289 - 1295.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Omori and J. Kotera
Overview of PDEs and Their Regulation
Circ. Res., February 16, 2007; 100(3): 309 - 327.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. T. Bender and J. A. Beavo
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. D. MacPherson, T. D. Gillespie, H. A. Dunkerley, D. H. Maurice, and B. M. Bennett
Inhibition of Phosphodiesterase 5 Selectively Reverses Nitrate Tolerance in the Venous Circulation
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 188 - 195.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
O. V. Evgenov, C. J. Busch, N. V. Evgenov, R. Liu, B. Petersen, G. E. Falkowski, B. Petho, A. Vas, K. D. Bloch, W. M. Zapol, et al.
Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L723 - L729.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. E. Bornfeldt
Nuclear Signaling in Smooth Muscle Cells: Cyclic Nucleotide Phosphodiesterase 1A Moves In
Circ. Res., March 31, 2006; 98(6): 720 - 722.
[Full Text] [PDF]


Home page
Circ. Res.Home page
D. J. Nagel, T. Aizawa, K.-I. Jeon, W. Liu, A. Mohan, H. Wei, J. M. Miano, V. A. Florio, P. Gao, V. A. Korshunov, et al.
Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival
Circ. Res., March 31, 2006; 98(6): 777 - 784.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Tahseldar-Roumieh, R. Ghali-Ghoul, C. Lugnier, and R. Sabra
Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H481 - H488.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Ding, J.-i. Abe, H. Wei, H. Xu, W. Che, T. Aizawa, W. Liu, C. A. Molina, J. Sadoshima, B. C. Blaxall, et al.
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis
PNAS, October 11, 2005; 102(41): 14771 - 14776.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Munzel, A. Daiber, and A. Mulsch
Explaining the Phenomenon of Nitrate Tolerance
Circ. Res., September 30, 2005; 97(7): 618 - 628.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
X. Pi, G. Garin, L. Xie, Q. Zheng, H. Wei, J.-i. Abe, C. Yan, and B. C. Berk
BMK1/ERK5 Is a Novel Regulator of Angiogenesis by Destabilizing Hypoxia Inducible Factor 1{alpha}
Circ. Res., June 10, 2005; 96(11): 1145 - 1151.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Watanabe, T. A. Barker, and B. C. Berk
Angiotensin II and the Endothelium: Diverse Signals and Effects
Hypertension, February 1, 2005; 45(2): 163 - 169.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter
Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase
Circulation, November 4, 2003; 108(18): 2172 - 2183.
[Full Text] [PDF]


Home page
Circ. Res.Home page
V. Gerzanich, A. Ivanov, S. Ivanova, J. B. Yang, H. Zhou, Y. Dong, and J. M. Simard
Alternative Splicing of cGMP-Dependent Protein Kinase I in Angiotensin-Hypertension: Novel Mechanism for Nitrate Tolerance in Vascular Smooth Muscle
Circ. Res., October 31, 2003; 93(9): 805 - 812.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Aizawa, H. Wei, J. M. Miano, J.-i. Abe, B. C. Berk, and C. Yan
Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells
Circ. Res., September 5, 2003; 93(5): 406 - 413.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. H. Maurice, D. Palmer, D. G. Tilley, H. A. Dunkerley, S. J. Netherton, D. R. Raymond, H. S. Elbatarny, and S. L. Jimmo
Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System
Mol. Pharmacol., September 1, 2003; 64(3): 533 - 546.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
Circ. Res., August 22, 2003; 93(4): 280 - 291.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Muller, U. Laber, J. Mullenheim, W. Meyer, and G. Kojda
Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1994 - 2000.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Yan, D. Kim, T. Aizawa, and B. C. Berk
Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator
Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Gori and J. D. Parker
Nitrate Tolerance: A Unifying Hypothesis
Circulation, November 5, 2002; 106(19): 2510 - 2513.
[Full Text] [PDF]


Home page
CirculationHome page
J. D. Parker and T. Gori
Tolerance to the Organic Nitrates: New Ideas, New Mechanisms, Continued Mystery
Circulation, November 6, 2001; 104(19): 2263 - 2265.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. D. Frame, R. J. Fox, D. Kim, A. Mohan, B. C. Berk, and C. Yan
Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2377 - H2385.
[Abstract] [Full Text] [PDF]